Population pharmacokinetics of oseltamivir and oseltamivir carboxylate in obese and Non-obese volunteers.

Population pharmacokinetics of oseltamivir and oseltamivir carboxylate in obese and Non-obese volunteers.

The aims of this study were to compare the pharmacokinetics of oseltamivir and oseltamivir carboxylate in obese and non-obese individuals and to determine the effect of obesity on the pharmacokinetic properties of oseltamivir and the active antiviral metabolite oseltamivir carboxylate.The population...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chairat, K, Jittamala, P, Hanpithakpong, W, Day, N, White, N, Pukrittayakamee, S, Tarning, J
Formato:	Journal article
Lenguaje:	English
Publicado:	Wiley 2016

Ejemplares similares

Pharmacokinetics of orally administered oseltamivir in healthy obese and nonobese Thai subjects.
por: Jittamala, P, et al.
Publicado: (2014)

Comparison of oseltamivir and oseltamivir carboxylate concentrations in venous plasma, venous blood, and capillary blood in healthy volunteers.
por: Instiaty, I, et al.
Publicado: (2013)

Pharmacokinetics of orally administered oseltamivir in healthy obese and nonobese thai subjects
por: Jittamala, P, et al.
Publicado: (2014)

Pharmacokinetics of high-dose oseltamivir in healthy volunteers.
por: Wattanagoon, Y, et al.
Publicado: (2009)

Effects of dexamethasone coadministered with oseltamivir on the pharmacokinetics of oseltamivir in healthy volunteers
por: Jang K, et al.
Publicado: (2017-03-01)

Development and validation of a liquid chromatographic-tandem mass spectrometric method for determination of oseltamivir and its metabolite oseltamivir carboxylate in plasma, saliva and urine.
por: Lindegårdh, N, et al.
Publicado: (2007)

An open-label crossover study to evaluate potential pharmacokinetic interactions between oral oseltamivir and intravenous zanamivir in healthy Thai adults.
por: Pukrittayakamee, S, et al.
Publicado: (2011)

An open-label crossover study to evaluate potential pharmacokinetic interactions between oral oseltamivir and intravenous zanamivir in healthy thai adults
por: Pukrittayakamee, S, et al.
Publicado: (2011)

Chemical analysis and transplacental transfer of oseltamivir and oseltamivir carboxylic acid in pregnant rats.
por: Chia-Chun Lin, et al.
Publicado: (2012-01-01)

Combination therapy with amantadine, oseltamivir and ribavirin for influenza A infection: safety and pharmacokinetics.
por: Seo, S, et al.
Publicado: (2013)

Plasma concentrations of oseltamivir and oseltamivir carboxylate in critically ill children on extracorporeal membrane oxygenation support.
por: Enno D Wildschut, et al.
Publicado: (2010-01-01)

Enantiospecific pharmacokinetics and drug-drug interactions of primaquine and blood-stage antimalarial drugs
por: Chairat, K, et al.
Publicado: (2018)

Oseltamivir Population Pharmacokinetics in the Ferret: Model Application for Pharmacokinetic/Pharmacodynamic Study Design.
por: Micaela B Reddy, et al.
Publicado: (2015-01-01)

Efficacy of oseltamivir treatment in influenza virus-infected obese mice
por: Rebekah Honce, et al.
Publicado: (2023-08-01)

Population pharmacokinetics and electrocardiographic effects of dihydroartemisinin-piperaquine in healthy volunteers
por: Chotsiri, P, et al.
Publicado: (2017)

Importance of collection tube during clinical studies of oseltamivir.
por: Lindegardh, N, et al.
Publicado: (2007)

Ode to Oseltamivir and Amantadine?
por: JM Conly, et al.
Publicado: (2006-01-01)

Combination therapy of nitazoxanide with oseltamivir compared with oseltamivir in hospitalized patients with seasonal influenza
por: Parvaiz A Koul, et al.
Publicado: (2024-01-01)

Rapid degradation of oseltamivir phosphate in clinical samples by plasma esterases.
por: Lindegardh, N, et al.
Publicado: (2006)

Oseltamivir and inhaled zanamivir as influenza prophylaxis in Thai health workers: a randomized, double-blind, placebo-controlled safety trial over 16 weeks.
por: Anekthananon, T, et al.
Publicado: (2013)

Impact of Oseltamivir and Diabetes Development
por: Bor-Show Tzang, et al.
Publicado: (2025-01-01)

Impact of oseltamivir on the risk of cancer
por: Pei-Hua Chuang, et al.
Publicado: (2024-02-01)

Rapid Emergence of Oseltamivir Resistance
por: Cheng Len Sy, et al.
Publicado: (2010-04-01)

Assay to Detect Oseltamivir Resistance
por: Kamol Suwannakarn, et al.
Publicado: (2006-12-01)

Oseltamivir in pregnancy and birth outcomes
por: Vera Ehrenstein, et al.
Publicado: (2018-10-01)

Impact of Oseltamivir Treatment on Influenza A and B Virus Dynamics in Human Volunteers
por: Kyla L. Hooker, et al.
Publicado: (2021-03-01)

Pharmacokinetic interactions between primaquine and chloroquine.
por: Pukrittayakamee, S, et al.
Publicado: (2014)

Strategies for the Use of Oseltamivir and Zanamivir during Pandemic Outbreaks
por: Elsa Hansen, et al.
Publicado: (2010-01-01)

OSELTAMIVIR MEDICATION IN THE PEDIATRIC PRACTICE: THE REVIEW
por: A.B. Ivanyuk, et al.
Publicado: (2008-01-01)

OSELTAMIVIR MEDICATION IN THE PEDIATRIC PRACTICE: THE REVIEW
por: A.B. Ivanyuk, et al.
Publicado: (2008-01-01)

Oseltamivir and G6PD deficiency
por: Şinasi Özsoylu
Publicado: (2010-06-01)

Oseltamivir and G6PD deficiency
por: Şinasi Özsoylu
Publicado: (2010-06-01)

Oseltamivir Enhances Hippocampal Network Synchronization
por: Atsushi Usami, et al.
Publicado: (2008-01-01)

Oseltamivir for the treatment of influenza in children and adolescents
por: Alfredo Tagarro, et al.
Publicado: (2019-05-01)

Inhibition of Influenza Virus Replication by Oseltamivir Derivatives
por: Renee W. Y. Chan, et al.
Publicado: (2022-02-01)

Oseltamivir and inhaled zanamivir as influenza prophylaxis in thai health workers: A randomized, double-blind, placebo-controlled safety trial over 16 weeks. [J Antimicrob Chemother 68, (2013) 697-707]
por: Anekthananon, T, et al.
Publicado: (2013)

A randomized, crossover study to evaluate the pharmacokinetics of amantadine and oseltamivir administered alone and in combination.
por: Dennis Morrison, et al.
Publicado: (2007-12-01)

Metabolism and disposition of oseltamivir (OS) in rats, determined by immunohistochemistry with monospecific antibody for OS or its active metabolite oseltamivir carboxylate (OC): A possibility of transporters dividing the drugs’ excretion into the bile and kidney
por: Kunio Fujiwara, et al.
Publicado: (2020-06-01)

Comparative effectiveness of combined favipiravir and oseltamivir therapy versus oseltamivir monotherapy in critically ill patients with influenza virus infection
por: Wang, Y, et al.
Publicado: (2019)

Safety and pharmacokinetic properties of a new formulation of parenteral artesunate in healthy Thai volunteers
por: Tarning, J, et al.
Publicado: (2024)